Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucosal Immunology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SETSIP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SETSIP Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native folding. |
View SETSIP Products |
| Gene Delivery | SETSIP Promise-ORF / Lentivirus Full-length ORF for stable overexpression in target cell lines. |
View SETSIP Products |
| Benchmark Ab | Anti-SETSIP Recombinant Antibody High-affinity positive control clone for neutralizing and binding assays. |
View SETSIP Products |
| Validator | SETSIP siRNA Set Target-specific knockdown verification in primary keratinocytes or colon epithelial cells. |
View SETSIP Products |
| Related Target A | GPR15 The primary cognate GPCR receptor for SETSIP, mediating T-cell homing to mucosal tissues. |
View GPR15 Products |
| Related Target B | CCR6 Synergistic chemokine receptor involved in mucosal immunity and psoriasis pathogenesis. |
View CCR6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native folding of small basic chemokines | HEK293 eukaryotic expression system ensuring correct disulfide bond formation and native conformation. |
| Endotoxin interference in immune cell assays | Strict endotoxin control (<1.0 EU/μg) to prevent non-specific activation of T cells and macrophages. |
| Lack of stable receptor-expressing cell lines | High-titer GPR15 Lentiviral Particles available for robust stable cell line construction (Flow Cytometry & Calcium Flux). |
| Assay specificity validation | Sequence-verified siRNA sets and validated benchmark recombinant antibodies included as positive controls. |
Live SETSIP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SETSIP therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to localized mucosal and epidermal target modulation. As first-generation therapies targeting the GPR15/SETSIP axis reach the clinic, the next wave of R&D is targeting highly selective neutralizing antibodies and small molecule antagonists to treat inflammatory bowel disease (IBD) and psoriasis without systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Boehringer Ingelheim, Amgen | Psoriasis, Atopic Dermatitis | Binding Affinity & Neutralization Assay (Need bioactive HEK293-expressed SETSIP) |
| Small Molecule Antagonist | Gilead, Novartis | Ulcerative Colitis, Crohn's Disease | Receptor Activation Blockade (Need GPR15 stable cell lines via Lentivirus) |
| Topical Therapeutics | Leo Pharma, Incyte | Plaque Psoriasis | Efficacy in primary keratinocytes (Need sequence-verified SETSIP siRNA controls) |